VNGLF - ETF AI Analysis
Top Page
Vanguard FTSE Developed Europe UCITS ETF Accum EUR (VNGLF)
VNGLF’s rating suggests it is a solid but not top-tier ETF, offering broad exposure to developed European markets with a mix of strengths and some areas of caution. High-quality holdings like HSBC, Novartis, and AstraZeneca, which show strong financial performance and positive outlooks, help support the fund’s overall quality, while names such as Shell and Allianz introduce some risk due to weaker technical trends and growth challenges. The main risk factor is that many of the top holdings are large European financial and healthcare companies, so the ETF’s performance is closely tied to how these sectors and the European economy perform.
VNGLF vs. SPDR S&P 500 ETF (SPY)
- AUM
- 3.21B
- Region
- Europe
- Expense Ratio
- 0.15%
- Beta
- 0.64
- Issuer
- Vanguard
- Inception Date
- Jul 23, 2019
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- FTSE Developed Europe Index
VNGLF Summary
VNGLF is a Vanguard ETF that follows the FTSE Developed Europe Index, giving you broad exposure to many companies across major European countries like the UK, Germany, and France. It owns well-known names such as Nestlé and HSBC, and it automatically reinvests dividends, which can help your investment grow over time through compounding. Investors might consider this ETF to diversify beyond their home market and gain long-term growth from developed European economies. A key risk is that its value can rise or fall with European stock markets, so your investment can go up and down.
How much will it cost me?
The Vanguard FTSE Developed Europe UCITS ETF (VNGLF) has an expense ratio of 0.1%, meaning you’ll pay $1 per year for every $1,000 invested. This is lower than average because the fund is passively managed, tracking the FTSE Developed Europe Index to keep costs down.
What would affect this ETF?
Positive drivers for VNGLF include potential economic growth in developed European countries like Germany, France, and the UK, which could boost the performance of its top holdings in sectors such as financials, healthcare, and technology. However, negative factors such as rising interest rates or geopolitical tensions in Europe could impact market stability and weigh on the ETF's performance. Additionally, sector-specific challenges, like regulatory changes in healthcare or energy, could affect the fund's returns.
VNGLF Top 10 Holdings
This Vanguard Europe ETF leans heavily on a mix of continental heavyweights, with ASML acting as the star performer, its rising share price giving the fund a clear tech-powered tailwind. Financials like HSBC, Santander, and Allianz are also pulling their weight, adding steady, if sometimes choppy, support. On the defensive side, health-care names Roche and Novartis are quietly contributing, while AstraZeneca has been lagging and Nestlé looks more mixed, slightly dulling the overall shine. The fund is firmly rooted in developed Europe, offering broad, region-focused exposure.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 4.88% | $380.44M | EUR 539.67B | 50.70% | 76Outperform |
 GB:HSBA | HSBC Holdings | 2.38% | $185.54M | GBP 218.81B | 19.37% | 80Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 CH:NOVN | Novartis AG | 1.87% | $145.68M | CHF 244.89B | 35.30% | 80Outperform |
 CH:NESN | Nestlé SA | 1.63% | $127.36M | CHF 217.87B | 9.36% | 71Outperform |
 GB:SHEL | Shell (UK) | 1.93% | $150.49M | GBP 229.30B | 40.01% | 73Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 DE:SIE | Siemens | 1.58% | $123.45M | EUR 202.50B | 7.55% | 74Outperform |
 ES:SAN | Banco Santander | 1.41% | $109.94M | EUR 147.13B | 15.63% | 73Outperform |
 DE:ALV | Allianz | 1.25% | $97.86M | EUR 166.13B | 23.20% | 67Neutral |
VNGLF Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VNGLF, the sentiment is Negative. The current price of 66.91 is above the 20-day moving average (MA) of 66.68, below the 50-day MA of 68.13, and below the 200-day MA of 67.02, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 47.82 is Neutral, neither overbought nor oversold. The STOCH value of 66.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VNGLF.
VNGLF Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| VNGLF | $66.91 | $72.00(7.62% Upside) | $3.21B | 0.15% | 63Neutral |
 IEUR | $74.40 | $88.41(18.83% Upside) | $9.55B | 0.09% | 63Neutral |
 EZU | $65.16 | $80.47(23.50% Upside) | $9.25B | 0.50% | 63Neutral |
 BBEU | $76.21 | $90.70(19.02% Upside) | $9.09B | 0.09% | 64Neutral |
 FEZ | $65.03 | $81.21(24.88% Upside) | $4.16B | 0.29% | 67Neutral |
 HEDJ | $55.68 | $66.31(19.09% Upside) | $1.73B | 0.58% | 60Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VNGLF | Vanguard FTSE Developed Europe UCITS ETF Accum EUR | 66.91 | 6.97 | 11.62% | |
| IEUR | iShares Core MSCI Europe ETF | 74.40 | 8.18 | 12.36% | |
| EZU | iShares MSCI Eurozone ETF | 65.16 | 4.69 | 7.75% | |
| BBEU | JPMorgan BetaBuilders Europe ETF | 76.21 | 8.17 | 12.01% | |
| FEZ | SPDR EURO STOXX 50 ETF | 65.03 | 4.16 | 6.84% | |
| HEDJ | WisdomTree Europe Hedged Equity Fund | 55.68 | 4.81 | 9.46% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.